QGEN
QIAGEN N.V.
Biological Products, (No Diagnostic Substances)- 売上
- $2.1bn
- 時価総額
- $9.0bn
株価 $41.45 · 100株 4,145円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $2.0bn | $2.0bn | $2.1bn |
| 成長率 | — | 0.7% | 5.7% |
| 総利益 | $1.2bn | $967m | $1.3bn |
| 総利益率 | 62.8% | 48.9% | 62.2% |
| 販管費 | $460m | $451m | $458m |
| 販管費率 | 23.4% | 22.8% | 21.9% |
| 営利 | $410m | $98m | $466m |
| 営利率 | 20.9% | 4.9% | 22.3% |
| 純利益 | $341m | $84m | $425m |
| PBR | 2.4 | 2.5 | 2.4 |
| PSR | 4.6 | 4.5 | 4.3 |
| PGPR | 7.3 | 9.3 | 6.9 |
| PER | 26 | 108 | 21 |
| ﾈｯﾄｷｬｯｼｭ | ▲$842m | ▲$728m | ▲$815m |
| EV/EBITDA | 16.0 | 32.3 | 14.9 |
| Rule of 40 | — | 6% | 28% |
| セールス効率 | — | — | 4,705% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）